Join us in marking 10 years since the launch of the #MinION! We're thrilled to unveil our MinION 10 year promo packs, featuring: • 10x MinION Flow Cells • 2x selected sequencing kits Don't miss out on this special offer. Find out more: https://bit.ly/3Vmj6BZ #10YearsON
Oxford Nanopore Technologies
Biotechnology Research
Our goal is to enable the analysis of anything, by anyone, anywhere.
About us
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
- Website
-
http://www.nanoporetech.com
External link for Oxford Nanopore Technologies
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Oxford
- Type
- Public Company
- Specialties
- DNA sequencing and Next Generation Sequencing
Locations
Employees at Oxford Nanopore Technologies
-
Bruce Ashford
Principal Linux Platform Engineer at Oxford Nanopore Technologies plc
-
Jordan Herman
SVP, General Counsel at Oxford Nanopore Technologies plc
-
Jonathan Ellard
Director, IT Programme Management at Oxford Nanopore Technologies Ltd
-
Roger Pettett
VP Informatics, Oxford Nanopore Technologies PLC
Updates
-
With ORG. one Heather Ritchie-Parker is generating reference genomes of endangered species. Find out how she's using this data to aid conservation by providing insight into species traits, evolution, and how best to protect them in a changing environment. More here: https://bit.ly/4aVQ2Hp #nanoporeconf
-
Surgical biopsies for cancer can be invasive with negative side effects. Read how Daniel Kim and team have developed a minimally invasive method for early cancer detection — using #nanopore technology to sequence cell-free RNAs from blood samples. Read here: https://bit.ly/3LkeAiU #WYMM
Case study: the potential of nanopore cell-free RNA sequencing for earlier cancer detection
nanoporetech.com
-
Meet the next generation of portable sequencing. Find out more.👇 MinION is a real-time, portable sequencer that can be used anywhere. It has been used in hundreds of research labs across the world, lowering the barrier to access genomic information. The Mk1D is the next generation of MinION and is currently in development. Register your interest here: https://bit.ly/3S0RL7O #10yearsON Already an MinION user? This year also marks 10 years since the first MinION was released. To celebrate this landmark we've launched our MinION 10 year promo packs, featuring: • 10x MinION Flow Cells • 2x selected sequencing kits Don't miss out on this special offer. Find out more here: https://bit.ly/3S0DQyw #10YearsON #AnythingAnyoneAnywhere
-
Oxford Nanopore Technologies reposted this
Professor of Cancer Genetics and Surgery, University of Birmingham; Deputy Director @ Birmingham CRUK ECMC
We are excited to show our latest attempt at a clinically meaningful clinical cancer genome with rapid turnaround (24 hours!) times using Oxford Nanopore Technologies sequencing technology for patients who need a rapid, whole genome assessment of their tumour and germline, (in this case a brain tumour patient) offering them: 👉 Full SNV and indel calling 👉 Unbiased mutational signatures (for therapy selection) – e.g. HRD 👉 Germline variants and pharmacogenomics (e.g. DYPD) 👉 Genomewide structural variant profiling at the DNA level (e.g. fusions) 👉 Reporting of tumour mutational burden & MSI status for IO 👉 Methylation classification if applicable We decided to do an experiment where we would sequence: 👉 A tumour genome from a patient in 24 hours using two flowcells (one tumour, one normal). 👉 Tumour came out of the patient and was immediately extracted and put on the sequencer on Friday morning 👉 We took the data at 24 hours (Sat am) and at the finish (Mon am) and compared them Essentially there was *no difference* in terms of the clinically actionable findings between 15X coverage (at 24 hours) and 30x coverage (at 72 hours) – generated all at Q20 quality. We found all kinds of exciting things including 👉 An actionable fusion (from DNA!) 👉 Druggable and clinically relevant target for small molecule therapy 👉 Full germline report 👉 Mutational signatures suggestive of a target for therapy All of this has been actioned already in our tumour board, within 4 days of the sample coming out.. (could have been less if it wasn't the weekend!) Hat tip to Elena Efstathiou for doing the sequencing, Joanne Stockton for the support as always and for the people who designed many great open-source software tools that contributed to this including Ruibang Luo, Hilary Elrick,Isidro Cortés Ciriano, Sigve Nakken and many others.
-
-
Don't miss your chance to join us in Boston! Phase 3 tickets are available until July 31st. See what you've been missing. #WYMM #nanoporeconf
Oxford Nanopore Technologies Community Meeting - 16th & 17th September at the SoWa Power Station in Boston - What a venue!!! 👇 Phase 3 prices only available in July: $399.00 (1 – 31 July) – AVAILABLE NOW 👇 Join us at the Nanopore Community Meeting 2024: Boston, hosted at SoWa Power Station, to hear from a fantastic line up of speakers who are using nanopore technology to gain new insights across a broad range of research areas. You’ll also have the opportunity to get hands-on with the technology, hear the latest from the Oxford Nanopore team, and of course network with other members of the Nanopore Community. 👇 Can’t make the event in person? The Boston Nanopore Community Meeting will also be streamed online if you’re not able to attend in person. 👇 Virtual tickets Free of charge – AVAILABLE NOW 👇 In-person tickets Earlybird offer: $149.00 (24 – 31 May) – SOLD OUT Phase 2: $299.00 (1 – 30 June) – SOLD OUT Phase 3: $399.00 (1 – 31 July) – AVAILABLE NOW Phase 4: $499.00 (1 – 30 August) Phase 5: $599.00 (1 – 16 September) 👇 https://lnkd.in/eqtSFg7X and check this out: https://lnkd.in/eQ5dbRFy
-
-
The genetics behind Parkinson’s disease is still widely misunderstood. Discover how Guillaume Cogan is using long #nanopore reads to identify complex areas of the genome, discovering novel information behind neurodegenerative diseases. Watch here: https://bit.ly/3xajf3E #nanoporeconf
-
Gene therapy holds great promise for the future of disease treatment. Rapid and accurate results are crucial for evaluating the quality of this approach. Find out how Kathleen Zeglinski is leveraging #nanopore sequencing to enhance the quality controls of these therapies. More here: https://bit.ly/4e9K2h0 #nanoporeconf
-
Want to know more about this first of its kind study? Catch up on Carika's talk here: https://lnkd.in/eZB8FWhx
A highlight from the 10th Anniversary of the Oxford Nanopore Technologies London Calling event was Dr Carika Weldon, MRSB, FIBMS study. A fascinating pilot study focused on Medicine for Breast Cancer in the Caribbean. 💠 Identifying unique genetic markers for Caribbean women 💠Using Oxford Nanopore Technologies for local, end-to-end testing in Bermuda 💠40% of cases BRCA1/BRCA2 positive, 60% negative - emphasizing the need for expanded testing 💠First identification of DNA mismatch repair gene variants in a minority population 💠The Geneyx Genomex Ltd. solution was used for tertiary analysis This study paves the way for the larger Caribbean Genome Project. Read on for more details on how this collaboration advances genomic research in diverse populations. Read the full study here: https://lnkd.in/dfeppg76 #londoncalling2024 #dna #CaribbeanGenomeProject #genomicresearch
-
-
Whole plasmids in a single read Discover how you can rapidly resolve entire plasmids with our streamlined end-to-end workflow. Make fast, informed decisions in disease outbreaks, food production, and biopharma QC. Check out our workflow to learn more: https://bit.ly/4cEUFXM What you're missing matters. #WYMM
Workflow: plasmid sequencing | Oxford Nanopore Technologies
nanoporetech.com